GLAXO.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 13:00):

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally...

Stats
Šios dienos apimtis	228 005
Vidutinė apimtis	166 204
Rinkos kapitalizacija	360.61B
EPS	INR0 ( 2024-02-11 )
Kita pelno data	( INR0 ) 2024-05-17
Last Dividend	INR32.00 ( 2023-06-30 )
Next Dividend	INR0 ( N/A )
P/E	68.03
ATR14	INR2.45 (0.11%)

Tūris Koreliacija

Ilgas: -0.06 (neutral)

Trumpas: -0.56 (weak negative)

Signal:(58.435) Neutral

GlaxoSmithKline Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
DALALSTCOM.NS	0.832

10 Labiausiai neigiamai susiję koreliacijos
LTGILTBEES.NS	-0.83
ANANDRATHI.NS	-0.821
KPIGLOBAL.NS	-0.807

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

GlaxoSmithKline Koreliacija - Valiuta/Žaliavos

-0.11
( neutral )

0.05
( neutral )

-0.17
( neutral )

-0.23
( neutral )

0.44
( neutral )

0.43
( neutral )

GlaxoSmithKline Finansinės ataskaitos

Annual	2022
Pajamos:	INR32.52B
Bruto pelnas:	INR19.67B (60.49 %)
EPS:	INR36.05

FY	2022
Pajamos:	INR32.52B
Bruto pelnas:	INR19.67B (60.49 %)
EPS:	INR36.05

FY	2022
Pajamos:	INR32.78B
Bruto pelnas:	INR18.28B (55.78 %)
EPS:	INR22.48

FY	2021
Pajamos:	INR31.99B
Bruto pelnas:	INR18.04B (56.40 %)
EPS:	INR21.14

Financial Reports:

No articles found.

GlaxoSmithKline Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR60.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR32.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

GlaxoSmithKline Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.28 - low (42.21%) | Divividend Growth Potential Score: 5.02 - Stable (0.44%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR3.50	2003-04-10
Last Dividend	INR32.00	2023-06-30
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	21	--
Total Paid Out	INR435.25	--
Avg. Dividend % Per Year	1.67%	--
Score	2.77	--
Div. Sustainability Score	4.28
Div.Growth Potential Score	5.02
Div. Directional Score	4.65	--

Next Divdend (Est)
(2025-04-07)

INR32.69 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.77

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR17.50	1.50%
2019	INR20.00	1.34%
2020	INR20.00	1.23%
2021	INR30.00	1.86%
2022	INR60.00	3.45%
2023	INR32.00	2.43%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SANDHAR.NS	Dividend Junior	2023-09-14	Annually	7	0.66%
LXCHEM.NS	Dividend Junior	2023-07-20	Annually	4	0.11%
GLENMARK.NS	Dividend Junior	2023-09-18	Annually	23	0.37%
ASIANPAINT.NS	Dividend Junior	2023-06-09	Semi-Annually	23	0.43%
TINPLATE.NS	Dividend Junior	2023-08-11	Annually	19	0.72%
PDMJEPAPER.NS	Dividend Junior	2023-08-03	Annually	9	0.65%
J&KBANK.NS	Dividend Junior	2023-08-17	Sporadic	22	0.47%
DATAMATICS.NS	Dividend Junior	2023-09-22	Annually	21	0.49%
SHYAMMETL.NS	Dividend Junior	2023-06-05	Semi-Annually	4	0.70%
MAXHEALTH.NS	Dividend Junior	2023-09-08	Insufficient data to determine frequency	2	0.07%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.160	1.500	6.81	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.322	1.500	7.53	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	519.54	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	6.24	2.00	7.92	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.24	2.00	6.88	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.604	1.000	3.27	3.27	[0.2 - 0.8]
operatingProfitMarginTTM	0.264	1.000	6.73	6.73	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.28

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	68.18	1.000	3.21	0	[1 - 100]
returnOnEquityTTM	0.322	2.50	8.41	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.24	2.00	7.92	10.00	[0 - 30]
dividendYielPercentageTTM	1.503	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.24	2.00	7.92	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.129	1.500	5.80	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0319	1.000	-1.702	0	[0.1 - 0.5]
Total Score				5.02

GlaxoSmithKline

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.